BillionToOne, Inc. (BLLN) News
Track canonical SquawkNews coverage tagged to BLLN, BillionToOne, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 13 indexed stories across 10 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Weekly Recap: Northstar reimbursement +29% and CMS 15% lab fee cuts
BillionToOne, Inc. Class A (NASDAQ:BLLN) saw Northstar Response test reimbursement jump 29% to $2,124, but looming MolDx coverage decisions and CMS’s phased lab fee cuts—capped at about 15% annually through 2029—could pr
NEWS | Sep 28, 2026, 11:03 AM UTC
M
BLLN Q2 revenue rises 64% with strong margins and oncology growth
BLLN reported 64% Q2 revenue growth and strong profitability, driven by gains in prenatal and oncology. The company said independent clinics drive most growth, while health system integration investments and new products
EQUITY | Sep 09, 2026, 07:08 PM UTC
L
BLLN - BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference
BLLN - BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference
EQUITY | Sep 02, 2026, 08:06 PM UTC
L
BillionToOne initiated at Buy by Canaccord Genuity
Canaccord Genuity initiated coverage of BillionToOne at Buy.
EQUITY | Sep 02, 2026, 03:52 PM UTC
L
BillionToOne launches Northstar Origin liquid biopsy test
BillionToOne launches Northstar Origin, a new liquid biopsy test to help identify tissue of origin.
EQUITY | Sep 01, 2026, 01:01 PM UTC
L
BillionToOne launches Northstar Origin liquid biopsy add-on test
BillionToOne introduced Northstar Origin, an add-on test using a single blood draw, to help identify tissue of origin. It also expanded the Northstar Select panel to 102 genes.
EQUITY | Sep 01, 2026, 01:00 PM UTC
L
BLLN - /C O R R E C T I O N -- BillionToOne/
BLLN - /C O R R E C T I O N -- BillionToOne/
EQUITY | Aug 19, 2026, 02:22 PM UTC
L
BLLN - Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Re
BLLN - Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions
EQUITY | Aug 18, 2026, 04:10 PM UTC
L
BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move
BillionToOne, Inc. (NASDAQ: BLLN ) shares fell 28.12% in Wednesday’s after-hours session after the company reported its second-quarter financial results. The stock closed Wednesday’s regular session up 5.43% at $149.97 b
EARNINGS | Aug 06, 2026, 06:01 AM UTC
L
BillionToOne Affirms FY2026 Sales Guidance of $450.000M-$465.000M vs $456.440M Est
BillionToOne (NASDAQ: BLLN ) affirms FY2026 sales outlook from $450.000 million-$465.000 million to $450.000 million-$465.000 million vs $456.440 million estimate.
EARNINGS | Aug 05, 2026, 08:14 PM UTC
L
BLLN - BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance
BLLN - BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance
EARNINGS | Aug 05, 2026, 08:06 PM UTC
L
Billiontoone Insider Sold Shares Worth $533,330, According to a Recent SEC Filing
() -- John Roderick ten Bosch, Senior Vice President, Laboratory Operations, on July 13, 2026, sold 4,251 shares in Billiontoone (BLLN) for $533,330. Following the Form 4 filing with the SEC, ten Bosch has control over a
GEOPOLITICS | Jul 15, 2026, 08:48 PM UTC
L
Billiontoone Insider Sold Shares Worth $1,576,276, According to a Recent SEC Filing
() -- Oguzhan Atay, Director, Chairman, and CEO, on July 09, 2026, sold 12,500 shares in Billiontoone (BLLN) for $1,576,276. SEC Filing: Copyright © 2026. All rights reserved. does not provide investment advice. Unauthor
REGULATION | Jul 13, 2026, 08:41 PM UTC